title: Reality testing in cancer treatment: the phase I trial of endostatin.
abstract: Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery which provides hope to the patient, support to caregivers, and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. The September 1999 Schwartz Center Rounds addressed the growing attention around the phase I trial of Endostatin. Endostatin represents a new treatment paradigm. It is an anti-angiogenic protein, an endogenous fragment of collagen XVIII. In an attempt to ensure a fair allocation of a very limited number of treatment slots in this classical phase I trial, a lottery was established. More than 1,400 patients enrolled within two days of the lottery, all vying for three places in the first cohort. Two contrasting cases are presented, each a potentially eligible patient. The discussion focuses on the dilemma presented by patients desperate for an unproven treatment and the responsibility of staff to explain and support without compounding the hype or suffocating the hope.
authors.affiliation: Kenneth B. Schwartz Center at Massachusetts General Hospital, Hematology-Oncology Department, Boston 02114-2617, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Ryan
authors.forename: R T
authors.initials: RT
authors.lastname: Penson
authors.forename: S
authors.initials: S
authors.lastname: Ahmed
authors.forename: B A
authors.initials: BA
authors.lastname: Chabner
authors.forename: T J
authors.initials: TJ
authors.lastname: Lynch
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D017321:Clinical Trials, Phase I as Topic; D003094:Collagen / Q000627:therapeutic use*; D043170:Collagen Type XVIII; D043169:Endostatins; D004992:Ethics, Medical; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000523:psychology*; D018579:Patient Selection; D010446:Peptide Fragments / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043170:Collagen Type XVIII; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen